You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed lymphoid malignancy

Showing 1 - 25 of 7,533
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma Trial in

Recruiting
  • Natural Killer/T-cell Lymphoma
  • +2 more
  • Seoul, Kangnamgu, Korea, Republic of
    Samsung Medical Center
Sep 22, 2021

Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy Trial in Canada, United States (AGS67E)

Completed
  • Relapsed Lymphoid Malignancy
  • Refractory Lymphoid Malignancy
  • Duarte, California
  • +4 more
Nov 27, 2020

Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma Trial in Richmond (mycophenolate mofetil, Sargramostim, Filgrastim)

Active, not recruiting
  • Hodgkin's Lymphoma
  • +17 more
  • mycophenolate mofetil
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 21, 2021

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 18, 2023

Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

Recruiting
  • Recurrent Acute Leukemia
  • +16 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Tumor, Plasma Cell, Lymphoma Trial in Toulouse (Comprehensive Geriatric Assessment)

Recruiting
  • Neoplasm, Plasma Cell
  • Lymphoma
  • Comprehensive Geriatric Assessment
  • Toulouse, France
    University Hospital Toulouse
Oct 12, 2022

Relapsed Lymphoid Malignancies, Refractory Lymphoid Malignancies Trial in Bentleigh (CN1, 0.5mg/kg and CN401, 400mg, CN1, 1mg/kg

Terminated
  • Relapsed Lymphoid Malignancies
  • Refractory Lymphoid Malignancies
  • CN1, 0.5mg/kg and CN401, 400mg
  • +4 more
  • Bentleigh, Victoria, Australia
    Monash Health - Monash Medical Centre
Oct 20, 2022

Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement

Recruiting
  • Lymphoma
  • +4 more
  • Vysis LSI MYC Break Apart Rearrangement Probe Kit
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)

Not yet recruiting
  • ALL, Childhood B-Cell
  • +2 more
  • Tafasitamab
  • (no location specified)
Nov 25, 2022

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

Hematologic Malignancies Trial in Shanghai (GNC-035)

Recruiting
  • Hematologic Malignancies
  • Guiyang, Guizhou, China
  • +3 more
Jan 13, 2023

Relapsed/Refractory B-cell Malignancies Trial (AC676)

Not yet recruiting
  • Relapsed/Refractory B-cell Malignancies
  • (no location specified)
Mar 27, 2023

CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)

Recruiting
  • CD7+ Acute Leukemia
  • CD7+ Lymphoma
  • anti-CD7 CAR-T
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Sep 18, 2022

International Leukemia Target Board

Not yet recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Advice
  • (no location specified)
Feb 25, 2022

Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)

Active, not recruiting
  • Recurrent Chronic Lymphoid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

Recruiting
  • Acute T-lymphoblastic Leukemia
  • Acute T-lymphoblastic Lymphoma
  • CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Lymphoma, Non-Hodgkin Trial (JNJ-87801493, JNJ-80948543, JNJ-75348780)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • (no location specified)
Nov 15, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 22, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 20, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 16, 2023

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +2 more
  • Best Practice
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022